KRAS G12C MUTANT SOLID TUMORS
Clinical trials for KRAS G12C MUTANT SOLID TUMORS explained in plain language.
Never miss a new study
Get alerted when new KRAS G12C MUTANT SOLID TUMORS trials appear
Sign up with your email to follow new studies for KRAS G12C MUTANT SOLID TUMORS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with KRAS mutation
Disease control OngoingThis study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 18, 2026 11:51 UTC
-
New combo therapy targets hard-to-treat KRAS G12C cancers
Disease control OngoingThis study tests a new drug called JDQ443 combined with other therapies in people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find safe doses and see if the combinations can shrink or control the cancer. About 74 adults with lun…
Matched conditions: KRAS G12C MUTANT SOLID TUMORS
Phase: PHASE1, PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 17, 2026 12:07 UTC